IDYA IDEAYA Biosciences, Inc.
Q3 2025 10-Q
IDEAYA Biosciences, Inc. (IDYA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • No newly added risk factors this quarter; critical accounting policies unchanged from 10-K filed February 18, 2025
- • Operating cash flows improved to positive $19.4M vs negative $125.9M in prior year driven by upfront Servier payment
Quarterly Financial SummaryXBRL
Revenue
$208M
Net Income
$119M
Operating Margin
52.2%
Net Margin
57.4%
ROE
10.9%
Total Assets
$1.2B
Source: XBRL data from IDEAYA Biosciences, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on IDEAYA Biosciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.